ClinicalTrials.gg
TerminatedNCT02670720OPuS-4Updated Feb 17, 2016

Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

A Phase 3 interventional study of avoralstat in Hereditary Angioedema and HAE, sponsored by BioCryst Pharmaceuticals. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by BioCryst Pharmaceuticals · Phase 3, Interventional, and Prevention

Why this study was terminated
preceding efficacy study of avoralstat in its current formulation was not significant and does not support continued development

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.

Enrollment
21st of 21
6 · median 54
Started
2015
with 1 other
Phase 3
7 of 22
2 open now
Registered
6th of 22
by date

Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 21st largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 6th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, or all of them as a file.
02

Study summary

This is an open-label study designed to evaluate the long-term safety of prophylactic avoralstat (500 mg three times daily) when given to approximately 150 patients with hereditary angioedema (HAE) for a duration of up to 72 weeks. The study will also evaluate the long-term efficacy and impact on quality of life of avoralstat prophylactic treatment.

03

Conditions studied

  • Hereditary Angioedema
  • HAE

Keywords

  • BCX4161
  • avoralstat
  • HAE
  • hereditary angioedema
  • prophylaxis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant, non-lactating females age ≥ 18 years.
  • Provide written, .
  • Prior completion of an avoralstat therapeutic study OR a confirmed diagnosis of HAE Type 1 or HAE Type 2.
  • Access to appropriate medication for the treatment of acute HAE attacks.
  • Adequate .

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breast feeding.
  • medical condition or medical history.
  • Abnormal screening , laboratory or urinalysis finding that is clinically significant.
  • drug exposure within 30 days (except avoralstat).
  • History of or current alcohol or drug abuse.
  • or active or infection.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    avoralstat

    Five avoralstat capsules (100 mg) to be taken three times daily by mouth

    Drug: avoralstat

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who discontinue due to a treatment-emergent adverse event, who experience a treatment-emergent serious AE, who experience a Grade 3 or 4 AE and who experience Grade 3 or 4 laboratory abnormalities

    Time frame: Up to 72 weeks

Secondary outcomes

  1. Angioedema attack rate (subject-reported HAE attacks normalized for time on study)

    Time frame: Up to 72 weeks

  2. Durability in response (assessed as subject-reported HAE attacks)

    Time frame: change over time through 72 weeks

  3. Proportion of subjects who discontinue avoralstat with a reason of lack of efficacy

    Time frame: Up to 72 weeks

  4. Quality of life as determined by the EQ-5D-5L

    Time frame: Up to 72 weeks

  5. Quality of life as determined by the Angioedema Quality of Life Questionnaire

    Time frame: Up to 72 weeks

07

Study locations

3 sites
  • Leuven, Belgium
  • Grenoble, France
  • Lille, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Feb 2, 2016
Start
Dec 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02670720
Responsible party
Sponsor
First posted
Feb 2, 2016
Start date
Dec 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Feb 17, 2016

Study contacts

Henriette Farkas, MD, PhD, DSc
principal investigator · Semmelweis University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avoralstat

Start the discussion